> Details

Glenthøj, Andreas; Jakobsen, Lasse H.; Sengeløv, Henrik; Ahmad, Syed A.; Qvist, Kristian; Rewes, Annika; Poulsen, Christian B.; Overgaard, Ulrik M.; Mølle, Ingolf; Severinsen, Marianne T.; Strandholdt, Casper N.; Maibom, Jack; Kodahl, Annette R.; Ryg, Jesper; Ravn, Pernille; Johansen, Isik S.; Helsø, Søren N.; Jensen‐Fangel, Søren; Kisielewicz, Jacek; Wiese, Lothar; Helleberg, Marie; Kirk, Ole; Clausen, Michael R.; Frederiksen, Henrik

SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: SARS‐CoV‐2 infection among patients with haematological disorders: Severity and one‐month outcome in 66 Danish patients in a nationwide cohort study
  • Contributor: Glenthøj, Andreas; Jakobsen, Lasse H.; Sengeløv, Henrik; Ahmad, Syed A.; Qvist, Kristian; Rewes, Annika; Poulsen, Christian B.; Overgaard, Ulrik M.; Mølle, Ingolf; Severinsen, Marianne T.; Strandholdt, Casper N.; Maibom, Jack; Kodahl, Annette R.; Ryg, Jesper; Ravn, Pernille; Johansen, Isik S.; Helsø, Søren N.; Jensen‐Fangel, Søren; Kisielewicz, Jacek; Wiese, Lothar; Helleberg, Marie; Kirk, Ole; Clausen, Michael R.; Frederiksen, Henrik
  • imprint: Wiley, 2021
  • Published in: European Journal of Haematology
  • Language: English
  • DOI: 10.1111/ejh.13519
  • ISSN: 0902-4441; 1600-0609
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>Patients with haematological disorders may be particularly vulnerable to respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection; however, this is unknown.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a prospective, nationwide study including 66 patients in follow‐up at Danish haematology departments with a malignant or non‐malignant haematological disorder and with verified SARS‐CoV‐2 infection. Outcomes were intensive care unit (ICU) admission and one‐month survival rate.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Mean age was 66.7 years, 60.6% were males, 90.9% had comorbidity, and 13.6% had a BMI ≥ 30. The most frequent diagnoses were chronic lymphocytic leukaemia/lymphoma (47.0%), multiple myeloma (16.7%) and acute leukaemia/myelodysplastic syndrome (AL/MDS) (12.1%). Treatment for the haematological disease was ongoing in 59.1% of cases. Neutropenia was present in 6.5%, lymphopenia in 46.6% and hypogammaglobulinaemia in 26.3%. The SARS‐CoV‐2 infection was mild in 50.0%, severe in 36.4% and critical in 13.6%. After one month, 21.2% had been admitted to ICU, and 24.2% died. Mortality was highest in older patients, patients with severe/critical SARS‐CoV‐2 infection, high comorbidity score or high performance status score, purine analogue treatment and with AL/MDS. Although older patients and patients with comorbidities had the highest mortality rates, mortality was considerable among all haematological patients.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Haematological patients with SARS‐CoV‐2 infection has a severe clinical course.</jats:p></jats:sec>